Real-World Clinical Inertia amongst T2DM Patients: Clinical, Physician, and Patient Viewpoints

被引：0
|
作者：
Higgins, Victoria
Leith, Andrea
Kelly, Melissa
Ellams, Amy
机构：
来源：
DIABETES | 2017年 / 66卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
664-P
引用
收藏
页码：A173 / A173
页数：1
相关论文
共 50 条
  • [21] Real-World (RW) treatment patterns in patients with T2DM newly initiated with antihyperglycemic (AHA) medications in the US
    Cai, Jennifer
    Burudpakdee, Chakkarin
    Divino, Victoria
    Fegade, Mayuresh
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S117 - S117
  • [22] Safety of Dapagliflozin in Clinical Trials for T2DM
    Ptaszynska, Agata
    Johnsson, Kristina M.
    Apanovitch, Anne Marie
    Sugg, Jennifer E.
    Parikh, Shamik J.
    List, James F.
    DIABETES, 2012, 61 : A258 - A259
  • [23] Clinical Inertia Is Increasing in Starting Insulin Therapy in T2DM: Results of the AMD Annals Initiative
    Rossi, Maria Chiara
    Pellegrini, Fabio
    Baccetti, Fabio
    Ceriello, Antonio
    Daros, Roberto
    Di Bartolo, Paolo
    Giorda, Carlo B.
    Marelli, Giuseppe
    Mulas, Maria Franca
    Nicolucci, Antonio
    Maria, Antonietta
    Vespasiani, Scarpitta Giacomo
    DIABETES, 2014, 63 : A618 - A619
  • [24] INTENSIFY: effectiveness of insulin degludec/liraglutide (IDegLira) in a real-world T2DM population in the UAE
    Al Awadi, F.
    Aly, H.
    Bashier, A.
    Benavente, J. Medina
    Dhanwal, D. Kumar
    Jallo, M.
    Singhal, S.
    Abusnana, S.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [25] Real-world treatment switching patterns in patients (pts) with type 2 diabetes mellitus (T2DM) on basal insulin (INS)
    Kapustin, J.
    Anderson, J. E.
    Reid, T.
    Rhinehart, A.
    Brunton, S.
    Stewart, J.
    Zhou, W.
    Dex, T.
    Kazemi, M.
    Vlajnic, A.
    Dalal, M.
    DIABETOLOGIA, 2014, 57 : S440 - S440
  • [26] Real-World Outcomes of Patients with Type 2 Diabetes Mellitus (T2DM) Treated with Canagliflozin in a US Managed Care Setting
    Chow, Wing
    Buysman, Erin K.
    Rupnow, Marcia F. T.
    Henk, Henry J.
    DIABETES, 2015, 64 : A347 - A348
  • [27] REAL-WORLD TREATMENT PATTERNS OF ANTIHYPERGLYCEMIC AGENTS AMONG PATIENTS WITH TYPE 2 DIABETES MELLTUS (T2DM) INITIATED ON CANAGLIFLOZIN
    Chow, W.
    Buysman, E. K.
    Rupnow, M. F.
    Henk, H. J.
    VALUE IN HEALTH, 2015, 18 (03) : A55 - A55
  • [28] Nonalcoholic Fatty Liver Disease (NAFLD) in Type 2 Diabetes Mellitus (T2DM) Patients in India: A Real-World Perspective
    Singh, Vikram Jit
    Singh, Manmohan
    Patidar, Hemant
    DIABETES, 2020, 69
  • [29] Impact of Diabetes Treatment-Related Attributes on Costs of Type 2 Diabetes (T2DM) Patients in a Real-World Population
    Lee, Yi-Chien
    Meng, Jie
    Casciano, Roman
    Perrin, Allison
    Gultyaev, Dmitry
    Tong, Liyue
    Kitio-Dschassi, Brice
    DIABETES, 2016, 65 : A323 - A323
  • [30] Therapeutically Exchangeable? A Real-World Outcome Study of Switching between Basal Insulin Analogs among T2DM Patients
    Levin, Philip
    Wei, Wenhui
    Miao, Raymond
    Xie, Lin
    Ye, Fen
    Baser, Onur
    Gill, Jasvinder K.
    DIABETES, 2014, 63 : A234 - A234
12345